P1014 Multicenter Real-World Outcomes of Risankizumab in Crohn’s Disease: The RESOLVE IG-IBD Study

Abstract The RESOLVE IG-IBD Study Group: Marina Aloi Mariangela Allocca Annalisa Aratari Marta Ascolani Paola Balestrieri Lorenzo Bertani Cristina Bezzio Giorgia Bodini Fabrizio Bossa Emma Calabrese Michele Campigotto Rosanna Cannatelli Flavio Caprioli Marica Cappello Pietro Capone Michele Cicala Giuseppe Cuccia Ferdinando D’Amico Silvio Danese Alice De Bernardi Francesca Romana De Filippo Elena Del Zanna Federico Desideri Dhanai Di Paolo Antonio Di Sario Massimo Claudio Fantini Concetta Ferracane Stefano Festa Gionata Fiorino Elisa Foscarini Federica Furfaro Roberto Gabbiadini Andrea Geccherle Viviana Gerardi Emiliano Giangreco Antonietta Gerarda Gravina Alfredo Greco Lucrezia Laterza Loris Riccardo Lopetuso Irene Marafini Mauro Mastronardi Marco Mendolaro Manuela Merli Giammarco Mocci Sara Onali Maria Francesca Onidi Alba Panarese Luca Pastorelli Raffaele Pellegrino Alessandra Piagnani Roberta Pica Maria Beatrice Principi Francesca Profeta Daniela Pugliese Davide Giuseppe Ribaldone Antonio Rispo Fernando Rizzello Ivan Salerno Fabrizio Santagata Simone Saibeni Edoardo Vincenzo Savarino Rocco Spagnuolo Enrico Tettoni Antonio Tursi Angela Variola Chiara Viganò. Background Risankizumab (RZB), a humanized IgG1 monoclonal antibody targeting the p19 subunit of IL-23, has recently been approved for the treatment of moderate-to-severe Crohn’s disease (CD). Given the limited real-world evidence available, this study aimed to evaluate the short- and long-term effectiveness and safety of RZB therapy in a large, real-life cohort of Italian CD patients. Methods From September 2023 to March 2025, all consecutive CD patients treated with RZB across 28 Italian centers were retrospectively enrolled. All patients completing the induction phase with a minimum 12-weeks-follow-up were included. The primary endpoints were steroid-free clinical remission (SFCR) (HBI